TWST vs. IOVA, NVAX, CBPO, VIR, RLAY, TECH, QGEN, PCVX, RVMD, and RGEN
Should you be buying Twist Bioscience stock or one of its competitors? The main competitors of Twist Bioscience include Iovance Biotherapeutics (IOVA), Novavax (NVAX), China Biologic Products (CBPO), Vir Biotechnology (VIR), Relay Therapeutics (RLAY), Bio-Techne (TECH), Qiagen (QGEN), Vaxcyte (PCVX), Revolution Medicines (RVMD), and Repligen (RGEN). These companies are all part of the "medical" sector.
Iovance Biotherapeutics (NASDAQ:IOVA) and Twist Bioscience (NASDAQ:TWST) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, community ranking, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.
Twist Bioscience has higher revenue and earnings than Iovance Biotherapeutics. Twist Bioscience is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Iovance Biotherapeutics currently has a consensus target price of $24.45, suggesting a potential upside of 164.37%. Twist Bioscience has a consensus target price of $49.75, suggesting a potential downside of 14.34%. Given Twist Bioscience's higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Twist Bioscience.
77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 10.4% of Iovance Biotherapeutics shares are owned by company insiders. Comparatively, 3.9% of Twist Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Twist Bioscience has a net margin of -69.24% compared to Twist Bioscience's net margin of -23,615.70%. Iovance Biotherapeutics' return on equity of -31.61% beat Twist Bioscience's return on equity.
Iovance Biotherapeutics has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500.
In the previous week, Twist Bioscience had 3 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 14 mentions for Twist Bioscience and 11 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 0.49 beat Twist Bioscience's score of 0.37 indicating that Twist Bioscience is being referred to more favorably in the news media.
Iovance Biotherapeutics received 469 more outperform votes than Twist Bioscience when rated by MarketBeat users. Likewise, 74.54% of users gave Iovance Biotherapeutics an outperform vote while only 57.76% of users gave Twist Bioscience an outperform vote.
Summary
Iovance Biotherapeutics beats Twist Bioscience on 9 of the 17 factors compared between the two stocks.
Get Twist Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for TWST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TWST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Twist Bioscience Competitors List
Related Companies and Tools
